Navigation Links
Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
Date:5/16/2008

MONTVALE, N.J., May 16 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced progress with several key development programs at its R&D Day meeting with the investment community. The Company reported new clinical data for MEM 1414, its lead PDE4 inhibitor, demonstrating the compound's CNS activity in humans. In addition, the Company has nominated MEM 68626 as the lead development candidate from its 5-HT6 antagonist program, and separately confirmed its 2008 development goals for its pipeline.

"We are extremely excited about the progress we have made in advancing our programs," said Vaughn M. Kailian, President and Chief Executive Officer of Memory Pharmaceuticals. "MEM 1414 produced a robust CNS signal in a human quantitative EEG study. In addition, using human whole blood assays, we have identified plasma concentrations required for anti-inflammatory activity. These data, combined with previous pharmacokinetic and safety data obtained in Phase 1 clinical trials for MEM 1414, will guide dosing for a proof-of-concept trial in either a cognition or respiratory indication, which we expect to initiate by the end of 2008."

Mr. Kailian continued, "Further, we are pleased to report that we have nominated MEM 68626 as the lead compound in our 5-HT6 antagonist program. MEM 68626 has demonstrated strong preclinical efficacy data in cognition and has a favorable safety and pharmacokinetic profile, which we believe offers advantages over other compounds in development. We look forward to advancing MEM 68626 into the clinic this year."

MEM 1414 - Potential in Cognition and Inflammation

Memory Pharmaceuticals reported the results of a clinical study of MEM 1414 on quantitative EEG (qEEG), a bio
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
2. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
3. Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimers Disease
4. Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia
5. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
6. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
7. How Big Is Your Brain? Its Size May Protect You from Memory Loss
8. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
9. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014  Eiger BioPharmaceuticals Incorporated announced the positive ... in patients with chronic hepatitis delta virus (HDV) ... Institutes of Health (NIH) Clinical Center in ... placebo-controlled, dose ascending study evaluated two doses of ... twice daily for 28 days.  "This proof-of-concept study ...
(Date:12/19/2014)... the Friday, December 19 edition of USA ... (HIT) features Konica Minolta, the company announced today. The supplement will ... healthcare organizations. In addition to the print section ... New York , Chicago , ... Minneapolis and San Francisco , ...
(Date:12/19/2014)... Dec. 19, 2014  Advanced Medical Isotope Corporation ... engaged primarily in the development of brachytherapy devices ... today announced that a Life Sciences Discovery Fund ... for which AMIC is the commercialization partner.  The ... for the proposal titled "Optimized Injectable Radiogels for ...
Breaking Medicine Technology:Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3USA Today Supplement Featuring Konica Minolta Focuses on Impact of Healthcare IT 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3
... 2007 /PRNewswire/ - Cytochroma Inc.,announced today positive data ... The initial top-line results from this trial,showed that ... are expected in August 2007. , The recently ... randomized study of CTA018 Injection,administered to 20 healthy ...
... PRINCETON, N.J.--(BUSINESS WIRE)--Jun 28, 2007 - Cytogen,Corporation ... Phase 1,dose escalation study evaluating QUADRAMET(R) (samarium ... Pharmaceuticals, Inc.) in patients with relapsed,multiple myeloma. ... in a,poster titled, "Phase 1 Trial of ...
Cached Medicine Technology:Cytochroma Reports Positive Phase I Clinical Data for CTA018,Injection 2Cytochroma Reports Positive Phase I Clinical Data for CTA018,Injection 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8
(Date:12/22/2014)... OH (PRWEB) December 22, 2014 Explorys, ... three additions to its leadership team: Greg Yarrington as ... of Engineering, and Patrick Wells as Vice President of ... to add 80 new jobs in 2015 to support ... expansion of its platform-as-a-service offerings, and growth of its ...
(Date:12/22/2014)... CA (PRWEB) December 22, 2014 ... now offering consultations for sleep apnea. Drowsy drivers are ... than drivers who are well-rested, and some experts believe ... the roads as intoxicated drivers. Unfortunately, millions of Americans ... the American Academy of Sleep Medicine, about 18 million ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Christmas is days ... has a fast and easy solution that will please: the ... can be purchased from from $25 up to $350," says ... 100% customer satisfaction and a wide array of skin care ... fees and no expiration dates. , Gift delivery past ...
(Date:12/22/2014)... Washington, DC (PRWEB) December 22, 2014 ... Nursing Leadership Conference, next month in San ... strategies to address dynamics that often stand in ... authority, and competition. , This premier faculty ... Center for Transformational Leadership, whose mission is to ...
(Date:12/21/2014)... (PRWEB) December 22, 2014 BellasDress.com offers ... more for women. Today, it announces its BellasDress ... products at its online store. , BellasDress is a ... benefits to its fans through a series of promotions. ... for every customer. , “We are proud of ...
Breaking Medicine News(10 mins):Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 3Health News:BellasDress.com Announces its BellasDress Christmas Sale 2
... development by a team of researchers at the University of ... medical procedures. , The system works by using a Web-based ... children from the procedures that cause the pain. The distractions ... watching a video, talking, or playing a game. , The ...
... is proud to announce,that President and CEO Humberto ... Jury President for North America. Jury members for ... their,achievements in the business, non-profit and academic fields, ... The awards, an annual distinction supporting innovative woman-led,business ...
... to Brooke Army Medical Center, RESTON, Va., ... ), an information technology and network solutions (IT),company, ... competitive task order under,the US Army,s HRsolutions Indefinite ... and Support to provide,services to Brooke Army Medical ...
... Illinois at Chicago has been named one of 10 ... consumers and clinicians make critical treatment decisions about therapeutic ... of the Agency for Healthcare Research and Quality,s Center ... It will design and test systems to optimize drug ...
... Oct. 16 (HealthDay News) -- A new gene associated with ... Dmp1 gene may help improve understanding of what ... , The Wake Forest University School of Medicine researchers analyzed ... the Dmp1 gene -- which normally works to ...
... 16 Starpharma,Holdings Ltd (ASX: SPL, Pink Sheets: ... SSL International plc (LSE: SSL), owner of Durex(R), ... which a commercial licence will be negotiated,sets out ... coating.,Undisclosed fees are payable to Starpharma under the ...
Cached Medicine News:Health News:UI researchers seek to ease children's pain during medical procedures 2Health News:UI researchers seek to ease children's pain during medical procedures 3Health News:Galderma Associates Itself to Cartier's Women's Initiative Awards to Recognize Female Entrepreneurs From Around the Globe 2Health News:Galderma Associates Itself to Cartier's Women's Initiative Awards to Recognize Female Entrepreneurs From Around the Globe 3Health News:SI International Awarded $4 Million Army HRsolutions Task Order 2Health News:SI International Awarded $4 Million Army HRsolutions Task Order 3Health News:New UIC center to study drug choices, safety 2Health News:Researchers ID New Gene Linked to Lung Cancer 2Health News:Starpharma and Durex Sign Co-Development Agreement for VivaGel(R)-Coated Condoms 2
Concave inner surface to conform to the globe. Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Wide scleral bed. Outside diameter 30.2 mm....
...
...
...
Medicine Products: